About
About Viridian Therapeutics, Inc
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Visit company website
5 years, 4 months ago
Viridian Therapeutics, Inc is currently in a long term uptrend where the price is trading 9.3% above its 200 day moving average.
From a valuation standpoint, the stock is 97.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 36.1.
Viridian Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 100.0% to $0 since the same quarter in the previous year.
Finally, its free cash flow grew by 99.9% to $-9K since the same quarter in the previous year.
Based on the above factors, Viridian Therapeutics, Inc gets an overall score of 4/5.